Illumina Inc. (ILMN): Today's Featured Drugs Laggard

Feb 12, 2014 5:01 PM EST

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Illumina ( ILMN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.3%. By the end of trading, Illumina fell $2.16 (-1.3%) to $158.94 on average volume. Throughout the day, 2,554,676 shares of Illumina exchanged hands as compared to its average daily volume of 1,706,100 shares. The stock ranged in price between $158.83-$162.31 after having opened the day at $161.58 as compared to the previous trading day's close of $161.10. Other companies within the Drugs industry that declined today were: Ventrus Biosciences ( VTUS), down 63.0%, OxiGene ( OXGN), down 24.6%, Galena Biopharma ( GALE), down 16.4% and Stemline Therapeutics ( STML), down 12.1%.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $20.4 billion and is part of the health care sector. Shares are up 45.7% year to date as of the close of trading on Tuesday. Currently there are 7 analysts that rate Illumina a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

You can view the full Illumina Ratings Report.

On the positive front, Ultragenyx Pharmaceutical ( RARE), up 11.6%, Skystar Bio-Pharmaceutical Company ( SKBI), up 11.3%, Seattle Genetics ( SGEN), up 10.7% and Vical Incorporated ( VICL), up 10.3% , were all gainers within the drugs industry with Biogen Idec ( BIIB) being today's featured drugs industry leader.

Use our drugs section to find industry-relevant news.
Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).